1 Heres what the 40-week results showed: HbA1c reductions: Tirzepatide 5 mg: reduced HbA1c by 2.01 percentage points Tirzepatide 10 mg: reduced HbA1c by 2.24 percentage points Tirzepatide 15 mg: reduced HbA1c by 2.30 percentage points Weight loss: Tirzepatide 5 mg: 7.6 kg (8.5% of body weight) Tirzepatide 10 mg: 9.3 kg (approximately 10% of body weight) Tirzepatide 15 mg: 11.2 kg (13.1% of body weight) Achieving target HbA1c: 92% of participants on 15 mg achieved HbA1c below 7% 51% achieved HbA1c below 5.7% (normal, non-diabetic range) These results were significantly better than semaglutide 1 mg (the comparison drug in the trial), where 81% achieved HbA1c below 7% and participants lost an average of 6.2 kg
Additionally, Tirzepatide helps reduce glucagon secretion, slows gastric emptying, and enhances feelings of fullness, making it easier for our patients to maintain healthy eating habits and manage their weight
How will semaglutide be integrated into my overall weight loss plan, and what lifestyle changes will be necessary
Certain foods interact poorly with slowed gastric emptying and altered gut motility
This dual mechanism can sometimes lead to greater improvements in blood sugar control and more significant weight loss for some patients compared to GLP-1 agonists alone
Every major medical organization recognizes obesity as a chronic disease, yet insurance and federal programs do not systematically cover people living with obesity for medical carethis needs to change, said Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA, in a statement
